PRDX4 and hepatocellular carcinoma: Guo et al. revealed that deletion of PRDX4 enhanced the risk of diethylnitrosamine- (DEN-) induced hepatocellular carcinoma in mice and low expression PRDX4 was significantly associated with poor prognosis in hepatocellular carcinoma patients.